Move over CAR-T: The potential of NK cells in cell therapy

from pharmaphorum Podcast · host pharmaphorum

On today’s podcast, Dr. Fred Aslan, CEO of Artiva Biosciences, joins host Jonah Comstock to talk more about this newer avenue in cell therapy. They discuss the potential of NK cells to provide effective allogeneic cell therapy, the potential of the therapy in auto-immune disease, and the importance of a robust manufacturing process that can get a high number of doses from a small amount of donated tissue.

Episode metadata supplied by the publisher feed · Published May 30, 2024

Embed this episode

Attribution link and audio player

NOW PLAYING

Move over CAR-T: The potential of NK cells in cell therapy

0:00 34:31

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of pharmaphorum Podcast?

This episode is 34 minutes long.

When was this pharmaphorum Podcast episode published?

This episode was published on May 30, 2024.

Can I download this pharmaphorum Podcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!